



## 2023 Multidisciplinary Thoracic Cancers Symposium · Planning Committee Disclosure of Relationships

The American Society for Radiation Oncology (ASTRO) is an Accreditation Council for Continuing Medical Education (ACCME)-accredited CME provider and complies with the ACCME Standards for Commercial Support. In accordance with these Standards, the ASTRO Conflict of Interest Policy and the Council for Medical Specialty Societies' Code for Interactions with Companies, ASTRO is disclosing here the relationships between faculty of the 2023 Multidisciplinary Thoracic Cancers Symposium and other entities related to oncology or radiation therapy.

### Explanatory notes:

- ASTRO uses the information disclosed to identify and manage any potential conflicts of interest that may arise in carrying out the responsibilities of the committees.
- Committee members disclose their own relationships and those of their immediate family members.
- There is no “minimum value” threshold for disclosure.
- Disclosure time period covers relationships held or payments received during the year leading up to the disclosure.
- The disclosure information is relevant only to the planning of the 2023 Multidisciplinary Thoracic Cancers Symposium and should be considered out of date after this time.
- This information may be different from disclosure information provided in other contexts by the committee members because of variation in disclosure requests for these other purposes.

**Employment** = positions held at the time of disclosure. These include both full- and part-time relationships, whether compensated or uncompensated.

**Compensation/Remuneration/Funding** = includes consultant/advisory roles, honoraria, research funding, travel expenses, in-kind donation, etc. If a committee member receives an honorarium and donates it to charity, the honorarium is disclosed. If a committee member declines an honorarium and it is paid directly to charity, the honorarium is not included. Honoraria from accredited CME providers are not included.

**Ownership or Investment Interests** = includes stock, stock options, partnership, royalties or patents. Stocks in mutual funds, blind trusts or other holdings that are not controlled by the individual or an immediate family member are not included.

**Leadership Positions** = positions held in other organizations or entities.

The ASTRO Conflict of Interest Policies are available at [www.astro.org/coipolicies](http://www.astro.org/coipolicies). Please direct any questions to [education@astro.org](mailto:education@astro.org).

**2023 Multidisciplinary Thoracic Cancers Symposium Steering Committee - Potential Conflict of Interest (COI) Disclosures**

Name	Employment	Compensation / Remuneration / Funding	Leadership Positions	Ownership or Investment Interests
David P. Carbone, MD, PhD	The Ohio State University Comprehensive Cancer Center: Professor	<b>Abbvie:</b> Consulting <b>AstraZeneca:</b> Consulting <b>BMS:</b> Consulting <b>Boehringer-Ingelheim:</b> Consulting <b>Daiichi-Sankyo:</b> Consulting <b>Eisai:</b> Consulting <b>Flame Biosciences:</b> Consulting <b>G1 Therapeutics:</b> Consulting <b>Genentech:</b> Consulting <b>Gritstone:</b> Consulting <b>Glaxo-Smith Kline:</b> Consulting <b>Iovance:</b> Consulting <b>Janssen:</b> Consulting <b>Jazz:</b> Consulting <b>JNJ:</b> Consulting <b>Merck:</b> Consulting <b>Merck KGaA:</b> Consulting <b>Mirati:</b> Consulting <b>Novartis:</b> Consulting <b>Novocure:</b> Consulting <b>OncoCyte:</b> Consulting <b>OncoHost:</b> Consulting <b>Pfizer:</b> Consulting <b>Regeneron:</b> Consulting <b>Roche China:</b> Consulting <b>Sanofi:</b> Consulting <b>Seattle Genetics, Inc.:</b> Consulting	None	None
Jamie Chافت, MD	Memorial Sloan Kettering Cancer Center: Associate Attending Physician	<b>Astra Zeneca:</b> Consultant, Research Grants <b>BMS:</b> Consultant, Research Grants <b>Merck:</b> Consultant, Research Grants <b>Novartis:</b> Research Grants <b>Genentech:</b> Consultant, Research Grants, Honoraria (uncompensated) <b>Arcus biosciences:</b> Consultant, Honoraria (Relationship ended 2023) <b>Guardant Health:</b> Consultant, Honoraria <b>Flame biosciences:</b> Consultant, Honoraria (Relationship ended 2022) <b>Regeneron:</b> Consultant, Honoraria (Relationship ended 2022)	None	None

Name	Employment	Compensation / Remuneration / Funding	Leadership Positions	Ownership or Investment Interests
<b>Marina Garassino, MD</b>	<b>University of Chicago:</b> Employee	<b>MSD Oncology:</b> Research Grants, Honoraria, Speaker's Bureau, Advisory Board <b>AstraZeneca/MedImmune:</b> Research Grants, Honoraria <b>AstraZeneca:</b> Research Grants, Travel Expenses, Advisory Board, Speaker's Bureau, Honoraria <b>Glaxo Smith Kline:</b> Research Grants, Honoraria Advisory Board <b>Takeda:</b> Research Grants, Honoraria, Advisory Board <b>Roche:</b> Research Grants, Honoraria, Travel Expenses, Advisory Board <b>Genentech:</b> Research Grants <b>Bristol Myers Squibb:</b> Research Grants, Honoraria, Advisory Board <b>Novartis:</b> Research Grants, Honoraria, Advisory Board <b>Sanofi/Aventis:</b> Research Grants, Advisory Board, Honoraria <b>Celgene:</b> Advisory Board <b>Daiichi Sankyo:</b> Speaker's Bureau, Honoraria, Advisory Board <b>Incyte:</b> Research Grants <b>Pfizer:</b> Research Grants, Honoraria, Travel Expenses, Advisory Board <b>Seattle Genetics:</b> Advisory Board <b>Eli Lilly:</b> Research Grants, Advisory Board <b>Bayer:</b> Advisory Board <b>Blueprint Medicines:</b> Research Grants, Honoraria, Advisory Board <b>Janssen:</b> Research Grants, Advisory Board <b>Mirati Therapeutics Inc:</b> Advisory Board, Speaker's Bureau <b>Regeneron:</b> Advisory Board, Honoraria <b>Exelixis:</b> Research Grants <b>Medimmune:</b> Research Grants <b>Merck:</b> Research Grants, Advisory Board, Speaker's Bureau <b>Spectrum Pharmaceuticals:</b> Research Grants <b>Abbvie:</b> Advisory Board <b>Boehringer Ingelheim:</b> Advisory Board <b>Ipsen:</b> Research Grants <b>Amgen:</b> Research Grants	None	None
<b>Biniam Kidane, MD, MS</b>	<b>Health Sciences Centre &amp; Shared Health:</b> Thoracic Surgeon	<b>AstraZeneca:</b> Advisory Board, Speaker Bureau, Consultant, Honoraria <b>Merck:</b> Advisory Board, Honoraria (Relationship ended 2022) <b>Medtronic:</b> Advisory Board, Honoraria (Relationship ended 2022)	<b>Canadian Association of Thoracic Surgeons:</b> Research committee chair <b>Journal of Thoracic &amp; Cardiovascular Surgery:</b> Associate Statistical Editor <b>Society of Thoracic Surgeons:</b> Work force member	None

Name	Employment	Compensation / Remuneration / Funding	Leadership Positions	Ownership or Investment Interests
Zhongxing Liao, MD, FASTRO	University of Texas MD Anderson Cancer Center: Professor of Radiation Oncology: Employee	AIQ, Inco: Advisory Board ReHava Bio: Consultant	None	None
Vickie R. Shannon, MD	University of Texas MD Anderson Cancer Center: Professor	None	None	None
Linda Williams Martin, MD, MPH	University of Virginia: Chief, Thoracic Surgery	AstraZeneca: Advisory Board, Honoraria, Travel Expenses Genentech: Advisory Board, Speaker Bureau, Honoraria, Travel Expenses On Target Laboratories: Advisory Board, Speaker Bureau, Honoraria, Travel Expenses Ethicon: Speaker Bureau, Honoraria	Alliance: Vice Chair, Respiratory Committee Commission on Cancer: Thoracic Surgeon representative of Society of Thoracic Surgeons to CoC American Association for Thoracic Surgery: Program Chair, perioperative track, May 2023 annual meeting IASLC: Meeting Co Chair	None
Sue Yom, MD, PhD, FASTRO	University of California San Francisco: Professor: Employee	Elsevier: Honoraria ASTRO: Honoraria Merck: Research Grants Bristol Myers Squibb: Research Grants EMD Serono: Research Grants	None	None
Mark M. Awad, MD, PhD	Dana Farber Cancer Institute: Employee	None	None	None
Kristin Higgins, MD	Emory University: Medical Director: Employee	AstraZeneca: Advisory Board, Consultant RefleXion Medical: Advisory Board, Compensation Payment Janssen Pharmaceuticals: Advisory Board, Consultant, Compensation Payment Genentech: Consultant Jazz Pharmaceuticals: Research Grants: Salary Support	NRG: General Director	None

Name	Employment	Compensation / Remuneration / Funding	Leadership Positions	Ownership or Investment Interests
<b>Ticiana A. Leal, MD</b>	<b>Emory University:</b> Associate Professor, Medical Thoracic Oncology Program Director	<b>Merck:</b> Honoraria, Advisory Board (Relationship ended: 11/17/2022) <b>Roche:</b> Honoraria (Relationship ended 11/18/2022) <b>Daiichi-Sankyo:</b> Honoraria (Relationship ended 11/11/2021) <b>Eisai:</b> Honoraria, Advisory Board (Relationship ended 11/17/2021) <b>Novocure:</b> Honoraria, Consultant, Advisory Board (Relationship ended 8/11/2022) <b>Amgen:</b> Honoraria (Relationship ended 1/21/2022) <b>Roche:</b> Honoraria (Relationship ended 2/12/2022) <b>AstraZeneca:</b> Honoraria (Relationship ended 7/8/2022) <b>Regeneron:</b> Consultant, Honoraria (Relationship ended 5/26/2022) <b>Takeda:</b> Honoraria (Relationship ended 8/12/2022)	None	None
<b>Percy Lee, MD</b>	<b>University of Texas MD Anderson Cancer Center:</b> Adjunct Professor <b>City of Hope National Medical Center:</b> Professor and Vice-Chair, Medical Director of Orange County and Coastal Regions	<b>Viewray:</b> Research Grants, Honoraria, Consultant, Travel Expenses <b>Varian, Inc.:</b> Honoraria <b>AstraZeneca:</b> Research Grants, Honoraria <b>Genentech:</b> Honoraria <b>RTOG Foundation:</b> Honoraria	<b>Radiosurgery Society:</b> Board of Director Member	None
<b>Philip A. Linden, MD</b>	<b>University Hospitals of Cleveland:</b> Chief, Thoracic and Esophageal Surgery: Employee	None	None	None
<b>Jason M. Long, MD, MPH</b>	<b>University of North Carolina School of Medicine:</b> Assistant Professor	<b>Intuitive:</b> Consultant <b>Stryker:</b> Consultant <b>Medscape:</b> Faculty	None	None

Name	Employment	Compensation / Remuneration / Funding	Leadership Positions	Ownership or Investment Interests
Kurt A. Schalper, MD	Yale University: Associate Professor: Employee	<b>Clinica Alemana de Santiago:</b> Honoraria, Consultant <b>Takeda:</b> Honoraria, Consultant, Research Grants <b>Boehringer-Ingelheim:</b> Research Grants <b>OnCusp:</b> Honoraria, Consultant (Relationship Ended: 2022) <b>Parthenon Therapeutics:</b> Honoraria, Consultant (Relationship Ended: 2021) <b>Bristol-Myers Squibb:</b> Advisory Board, Honoraria, Consultant (Relationship Ended: 2022) <b>CDR Life:</b> Honoraria, Consultant (Relationship Ended: 2022) <b>Roche:</b> Honoraria, Advisory Board <b>Sensei Therapeutics:</b> Honoraria, Advisory Board (Relationship Ended: 2022) <b>Molecular Templates:</b> Honoraria, Consultant <b>Shattuck Labs:</b> Honoraria, Advisory Board <b>Akoya Biosciences:</b> Research Grants <b>Agenus:</b> Honoraria, Consultant <b>Tesaro/GSK:</b> Research Grants (Relationship Ended: 2022) <b>Surface Oncology:</b> Research Grants (Relationship Ended: 2022) <b>Merck:</b> Research Grants, Speaker Bureau, Honoraria <b>Ribon Therapeutics:</b> Research Grants <b>AstraZeneca:</b> Research Grants, Honoraria	None	None
Thomas E. Stinchcombe, MD	Duke Cancer Care: Professor: Employee	<b>EMD Serono:</b> Advisory Board, Honoraria (Relationship Ended 2021) <b>Turning Point Therapeutics:</b> Advisory Board, Honoraria (Relationship Ended 2021) <b>Sanofi/Aventis:</b> Advisory Board, Honoraria (Relationship Ended 2022) <b>GlaxoSmithKline:</b> Honoraria: Other (DSMB) <b>Genentech/Roche:</b> Advisory Board, Research Grants, Honoraria <b>Daiichi Sankyo/Astra Zeneca:</b> Advisory Board, Honoraria <b>AstraZeneca:</b> Advisory Board (Relationship Ended 2022) <b>AstraZeneca:</b> Research Grants (Relationship Ended 2022) <b>Eisai/H3 Biomedicine:</b> Advisory Board, Honoraria (Relationship Ended 2022) <b>G1 Therapeutics:</b> Advisory Board: Honoraria (Relationship Ended 2022) <b>Spectrum Pharmaceuticals:</b> Advisory Board, Honoraria (Relationship Ended 2022) <b>Seagen:</b> Research Grants <b>Mirati Therapeutics:</b> Research Grants	None	None

		<b>Janssen Oncology:</b> Advisory Board, Honoraria (Relationship Ended 2022) <b>Takeda:</b> Research Grants (Relationship Ended 2022)		
--	--	--	--	--